Drug-induced movement disorders encompass a range of involuntary motor disturbances precipitated by exposure to certain medications, most commonly dopamine-blocking agents such as antipsychotics and ...

Parkinson's disease is the second most common neurodegenerative disease, affecting over 10 million people worldwide. Some forms of Parkinson's disease are characterized by an inability of cells to ...

New discussion around Parkinson’s treatment is putting dopamine agonists under the spotlight, with clinicians balancing motor ...

The EMA approves a new formulation of a levodopa-carbidopa combination to treat moderate-to-severe motor fluctuations in patients with Parkinson’s disease.

The cancer drug, Tasigna (nilotinib), was developed by pharmaceutical company Novartis AG to treat leukemia patients. To put it in simple terms, nilotinib activates a system in cells that works like a ...

The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people with the disease more control over their movements. Subscribe to our ...

Remepy, a pioneer in Hybrid Drugs™, today announced the publication of new mechanistic findings in npj Parkinson's Disease (Nature Portfolio). The study provides insight, for the first time, into ...

Parkinson’s disease is a long-term brain disorder that slowly damages nerve cells involved in movement. It affects millions of people around the world and becomes more common with age. The disease is ...

Not every hand tremor is a sign of Parkinson’s disease. In fact, neurologists say the vast majority of people who develop ...